Ergebnisse & FinanzlageGesundheit – Pharma – Biotechnologie
DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years
12.11.2026 16:00
AMFSofortige Veröffentlichung
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that new data from the successful Phase 3 VITESSE clinical trial of the VIASKIN® Peanut Patch in peanut-allergic children aged 4 to 7 years were highlighted in…
DBV Technologies Highlights New Data from the
VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years
- Additional VITESSE data being presented at 2026 ACAAI Annual Scientific Meeting support safety and efficacy findings from the phase 3 study, and assess potential practical aspects of daily use if approved
- VIASKIN® Peanut Patch treatment was associated with statistically significant reductions in reaction severity during the double-blind, placebocontrolled food challenges after 12 months, including reductions when reactions were assessed at or below participants’ baseline eliciting dose
- Mean treatment compliance was 96.1%; most study participants reported patches were easy and not painful to remove, and no restrictions on daily activities or concomitant medications were required in the study protocol
- VITESSE participants receiving the VIASKIN® Peanut Patch had immunologic changes consistent with allergen immunotherapy, including increased peanut-specific IgG4 and decreased peanut-specific IgE, Ara h 2 IgE and skinprick-test wheal diameter
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that new data from the successful Phase 3 VITESSE clinical trial of the VIASKIN® Peanut Patch in peanut-allergic children aged 4 to 7 years were highlighted in three presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona. The three presentations evaluate changes in allergic reaction severity during double-blind, placebo-controlled food challenges, the potential practicality of the VIASKIN® Peanut Patch using epicutaneous immunotherapy (EPIT), and changes to immunologic biomarkers during the 12- month VITESSE study.
VITESSE, the largest food allergy immunotherapy trial to date, randomized 654 children 2:1 to receive the VIASKIN Peanut Patch containing 250 μg of peanut protein (VP250) or placebo for 12 months. The study met its primary endpoint, with 46.6% of children in the VIASKIN Peanut Patch arm meeting treatment responder criteria at month 12 compared with 14.8% in the placebo arm (difference in response rates = 31.8%; 95% confidence interval [CI]: 24.5%, 39.0%; p<0.001).
Châtillon, France, November 12, 2026
“The VITESSE data presented at ACAAI add important context to the study’s overall positive results,” said Pharis Mohideen, M.D., Chief Medical Officer of DBV Technologies. “After one year of treatment, children receiving the VIASKIN® Peanut Patch in the study had statistically significantly lower maximum symptom severity during food challenge, along with immunologic changes consistent with other forms of allergen immunotherapy. I am also pleased that the practicality data show high treatment compliance in young children with common atopic comorbidities, and that all participants were able to continue their typical daily activities, including bathing, sports and swimming, while on treatment.” Highlights from the VITESSE data presented at ACAAI 2026: